Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Sep
20
Today In Oncology
Losing Weight and Breast Cancer Risk? The GLP-1 Question
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo